5 Key Takeaways
-
1
Minimally invasive bleb surgery (MIBS) aims to enhance glaucoma treatment by bridging the efficacy-safety gap of traditional surgeries.
-
2
MIBS technologies could expand treatment options for glaucoma patients, potentially moving procedures from the operating room to clinics.
-
3
The Xen 45 gel stent is the most recognized MIBS option in the U.S., but its outcomes have not yet matched those of trabeculectomy.
-
4
Investigational devices like the PreserFlo MicroShunt and Calibreye shunt show promise in improving safety and efficacy in glaucoma care.
-
5
Emerging nonimplant approaches, such as Aqualumin and Hexiris's Obi Ex, are also being developed for minimally invasive glaucoma treatment.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.